Dr. Simeone is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3855 Health Sciences Dr
La Jolla, CA 92093Phone+1 800-926-8273
Summary
- Dr. Diane Simeone is the Laura and Isaac Professor of Surgery and Pathology at New York University and the Director of the Pancreatic Cancer Center. She also serves as the Associate Director for Translational Research for the Perlmutter Cancer Center at NYU. An internationally renowned pancreatic surgeon and researcher with a long-standing career focus on the treatment of pancreatic cancer and pancreatic cystic tumors, she has performed over 1000 pancreatic resections using state-of-the art techniques. She has been an innovator in the development of therapeutic clinical trials for pancreatic cancer, and along with her team runs a large clinical research program dedicated to developing an early detection blood test for pancreatic cancer. She is currently the principal investigator of Precision Promise, an exciting new national clinical trials consortium focused on next-generation clinical trials for patients with pancreatic cancer. Dr. Simeone has published more than 175 studies in leading peer-reviewed journals and currently serves as the chair of the scientific and medical advisory board of the Pancreatic Cancer Action Network and is a member of the scientific advisory board for Let’s Win (Sharing Science Solutions for Pancreatic Cancer). She has previously served as the president of the Society of University Surgeons and the American Pancreatic Association. Dr. Simeone is a member of the Institute of Medicine of the National Academy of Sciences and the National Cancer Institute’s Pancreatic Cancer Task Force.
Education & Training
- University of Michigan Ross School of BusinessCertified Professional Innovator Program, Scientific Innovation, 2015 - 2015
- University of MichiganResidency, Surgery, 1988 - 1995
- Duke University School of MedicineClass of 1988
Certifications & Licensure
- FL State Medical License 2021 - Present
- CA State Medical License 2024 - 2026
- MI State Medical License 1991 - 2025
- CT State Medical License 2022 - 2024
- NY State Medical License 2017 - 2024
- American Board of Surgery Surgery
Awards, Honors, & Recognition
- America's Top Doctors for Cancer Castle Connolly, 2009-2014, 2016, 2105
- Chair, Scientific and Medical Advisory Board Pancreatic Cancer Action Network, 2017
- America's Top Doctors Castle Connolly, 2009-2016
- Join now to see all
Clinical Trials
- Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing Start of enrollment: 2021 Oct 29
Publications & Presentations
PubMed
- Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2.Serena Lucotti, Yusuke Ogitani, Candia M Kenific, Jacob Geri, Young Hun Kim
Cell. 2025-03-20 - Longitudinal assessment of disparities in pancreatic cancer care: A retrospective analysis of the National Cancer Database.Mahip Grewal, Victor J Kroon, Sarah R Kaslow, Anthony M Sorrentino, Megan D Winner
World Journal of Surgery. 2025-01-01 - The role of family history in predicting germline pathogenic variant carriers who develop pancreatic cancer: Results of a multicenter collaboration.Eve Karloski, Beth Dudley, Brenda Diergaarde, Amie Blanco, Jessica N Everett
Cancer. 2024-10-01
Journal Articles
- Tunable Thermal‐Sensitive Polymer–Graphene Oxide Composite for Efficient Capture and Release of Viable Circulating Tumor CellsDiane M Simeone, Monika L Burness, Max S Wicha, Advanced Materials
Press Mentions
- Cancer’s Ripple Effect May Promote Blood Clots in LungsFebruary 12th, 2025
- Lung Signals Trigger Blood Clot Formation in Cancer PatientsFebruary 10th, 2025
- Study: Breast Cancer Drug Shows Potential for Rare Appendix CancerOctober 16th, 2024
- Join now to see all
Grant Support
- Biomarker Validation in Pancreatic Cystic NeoplasmsUNIVERSITY OF CALIFORNIA, SAN DIEGO2023–2028
- Biomarker Validation in Pancreatic Cystic NeoplasmsUNIVERSITY OF CALIFORNIA, SAN DIEGO2023–2028
- POLQ Synthetic Lethality in HR-Deficient Pancreatic AdenocarcinomaUNIVERSITY OF CALIFORNIA, SAN DIEGO2020–2025
- POLQ Synthetic Lethality in HR-Deficient Pancreatic AdenocarcinomaUNIVERSITY OF CALIFORNIA, SAN DIEGO2020–2025
- Specialized Cancer Center Support GrantUNIVERSITY OF CALIFORNIA, SAN DIEGO1996–2025
- Specialized Cancer Center Support GrantUNIVERSITY OF CALIFORNIA, SAN DIEGO1996–2025
- Specialized Cancer Center Support GrantUNIVERSITY OF CALIFORNIA, SAN DIEGO1996–2025
- Precision Promise National Clinical Trial ConsortiumPancreatic Cancer Action Network2016–2021
- Prospective Study of the IMMray PanCan-d Test for the Early Detection of Pancreatic CancerImmunovia2016–2020
- ATDC Function in Human Pancreatic AdenocarcinomaNIH R012015–2020
- Oncogenic Function of ATDC in Bladder CancerNIH R012014–2019
- development of a Robust Family History Tool for Pancreatic CancerRolfe Foundation2017–2018
- CTC Personalized TherapeuticsLustgarten Foundation2015–2018
Research History
- Associate Director for Translational Research, Perlmutter Cancer CenterI guide translational research development in different disease groups in the cancer center to enhance translational and clinical rollout of impactful scientific findings2017 - 2025
- Director, Pancreatic Cancer CenterI direct the research development from basic, translational to clinical for pancreatic cancer at the institution2017 - 2025
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: